FDA Streamlines Medical Device Approvals with New Real-World Evidence Guidance
The Food and Drug Administration announced a significant policy shift today, paving the way for faster medical device approvals by accepting real-world evidence (RWE) without requiring individual patient data.
The FDA’s new guidance removes a major hurdle that previously limited the use of extensive, de-identified datasets in product applications. Previously, the agency mandated the inclusion of private, confidential information at the individual patient level for submissions utilizing RWE. This requirement effectively excluded many large databases containing aggregate or de-identified data, hindering the potential of readily available real-world insights.
The change represents a substantial move toward leveraging the power of big data in healthcare. While RWE has seen increasing adoption, its impact has varied across different product types. Since 2016, only 35 drugs, biologics, or vaccines have incorporated RWE into their applications. In contrast, over 250 premarket authorizations for medical devices have included RWE during the same period. However, even within the device sector, the FDA noted that the rate of RWE-supported approvals has begun to plateau in recent years.
The agency emphasized that the updated guidance aligns with the views of sponsors and data scientists, who have long maintained that valuable insights can be extracted from large data sources without needing access to personally identifiable patient information. Going forward, FDA reviewers will assess the validity of submitted RWE on a case-by-case basis, focusing on the strength of the evidence presented.
This shift unlocks access to a wealth of data, including national cancer registries, hospital databases, insurance claims data, and electronic health record networks. The National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) Program – which tracks cancer patients and their outcomes – is a prime example of a resource that will become more readily usable. According to the National Cancer Institute, SEER “provides information on cancer statistics in an effort to reduce the cancer burden among the US population.” While SEER and similar resources have grown significantly over time, their utility was previously constrained by the FDA’s stricter data requirements.
“We’re removing unnecessary barriers that have prevented us from using powerful real-world evidence to get life-changing treatments to patients faster,” stated FDA Commissioner Marty Makary, MD, MPH, in a news release. “This common-sense reform will unlock access to vast databases like cancer and cystic fibrosis registries that contain critical insights about how treatments work in the real world.”
Building on this change, the FDA also indicated its intention to explore updates to its guidance regarding the use of RWE for drugs and biologics, potentially broadening the impact of this policy shift across the entire spectrum of medical products.
References:
- FDA eliminates major barrier to using real-world evidence in drug and device application reviews. News release. FDA. December 15, 2025. Accessed December 15, 2025. https://www.fda.gov/news-events/press-announcements/fda-eliminates-major-barrier-using-real-world-evidence-drug-and-device-application-reviews
- Surveillance, Epidemiology, and End Results Program (SEER). Healthy People 2030. Accessed December 15, 2025. https://odphp.health.gov/healthypeople/objectives-and-data/data-sources-and-methods/data-sources/surveillance-epidemiology-and-end-results-program-seer
- Surveillance, Epidemiology, and End Results Program. National Cancer Institute. Accessed December 15, 2025. https://seer.cancer.gov/
